Thomas Burnell, PhD.

Thomas Burnell, PhD.

President and CEO, Interpace Biosciences

With a reputation as a visionary and transformational leader, Thomas W. Burnell has amassed a wealth of experience in the healthcare, biotechnology, laboratory sciences, and manufacturing industries. Tom’s uniquely effective approach to fostering cultures of excellence, and his focus on people, have led to significant achievements in growing and improving the profitability, performance, and value of companies. Over the course of his career, he has created over $1 billion in shareholder value.

Tom has an outstanding track record of effectively leading organizational change and orchestrating turnarounds, as well as accelerating growth for startups and facilitating post-acquisition integration. With international business development experience spanning 38 countries on five continents, he has achieved triple-digit EBITDA growth in several businesses and has facilitated 39 M&A transactions on the buy and sell sides combined.

Tom is President and CEO of Interpace Biosciences, a fully integrated commercial and bioinformatics company, that provides evidence-based, clinically beneficial molecular diagnostic tests and pathology services.

He co-founded Milestone Business Management, LLC, a consulting firm providing professional services to food, pharmaceutical, and life science companies, where he continues to serve as a General Partner. He also served as Interim President and CEO of Boston Heart Diagnostics, as well as Pioneer Heart Institute where he remains as Chairman of the Board.

He was a former Operating Partner at Ampersand Capital Partners, a middle-market growth equity firm, where he served as President, CEO, and Executive Chairman of Elite One Source Nutrisciences, Inc. and Executive Chairman of Accuratus Lab Services.

Additionally, Tom was President and CEO and Member of the Board of Directors at Viracor-IBT Laboratories, Inc. While maintaining his seat on the Board of Directors, he served as President and CEO of Nebraska Heart Institute (NHI) and Nebraska Heart Hospital (NHH). Tom joined NHI and NHH from Eurofins Scientific, Inc., where he served as President, CEO, Vice Chairman, and member of the Group Executive Committee. Previously, Tom was President and CEO of the startup company GenomicFX, Inc.

He has a B.S. in Animal Science and an M.S. in Animal Nutrition from the University of Nebraska, and a Ph.D. in Nutrition, with an emphasis in Statistics and Biochemistry, from the University of Kentucky.

Alidad Mireskandari, Ph.D. MBA

Alidad Mireskandari, Ph.D. MBA

Chief Development Officer, Interpace Biosciences

Alidad Mireskandari brings over 10 years of experience in molecular diagnostics and genetic testing to Interpace Biosciences. He has experience in product development, regulatory assurance, business development and reimbursement; and has led the development and commercialization of a number of diagnostic products on multiple technology platforms.

Prior to joining Interpace, Mr. Mireskandari was President & CEO of JS Genetics, a start-up company, overseeing the introduction of 3 products to market using technologies licensed from Yale University. Mr. Mireskandari also managed R&D activities and built operational capabilities of commercial laboratory to include CLIA license certification, CAP accreditation and NY state licensure. 

From 2000-2009, Mr. Mireskandari was a Hedge Fund Manager in charge of Life Sciences trading portfolios of Nomura Securities, BNP Paribas and Raeburn Advisors.  Prior to that Mireskandari was research fellow at NIH’s Nation Cancer Institute in Bethesda MD.

Syd Finkelstein

Syd Finkelstein

Chief Scientific Officer, Interpace Diagnostics

Dr. Finkelstein is a board certified pathologist specializing in gastrointestinal pathology with extensive experience in molecular diagnostics. He is the Adjunct Professor of Pathology, Drexel University on the faculty of Allegheny General Hospital, Pittsburgh, PA. He is the founder of RedPath Integrated Pathology, which was acquired by Interpace Diagnostics in 2014.

Tom Freeburg

Chief Financial Officer, Interpace Biosciences

Mr. Freeburg has been with Interpace since 2017 and brings over 20 years of financial and executive experience to his new role. As Chief Accounting Officer, he has led the company's Financial Reporting, Treasury, Financial Planning and Analysis (FP&A), Risk Management & Insurance and Corporate Development functions. Prior to Interpace, Tom served in senior finance roles at several other companies, where his responsibilities included Financial Reporting, Capital Markets, Treasury and FP&A.